The COVID-19 pandemic has fundamentally impacted all aspects of human life and put immense pressure on healthcare systems. For patients with chronic liver diseases, concerns have been raised about what the next few months will reveal in terms of increased morbidity and mortality resulting from delayed care and missed diagnoses. The impact of COVID-19 on achieving the WHO viral hepatitis elimination goals also cannot be forgotten.

View the footage from the symposium on demand to hear the expert faculty give a practical account of their ‘new normal’ as they discuss the strategies they have personally implemented to recover momentum towards the WHO viral hepatitis elimination goals in their hospitals, while Ivan Gardini (EpaC Onlus, Italy) provides the perspective from affected communities and reinforces the message that simplicity is what is needed both now and in the future as he shares his unique success story of co-screening in Italy.

Educational content

Presentations with accompanying slides are available to view by clicking the videos below.

By downloading these slides you are confirming that you are doing so for your personal education or to assist you with your clinical practice only. You agree that you will not use them for any other purpose without the prior permission of Gilead Sciences Europe Limited.

 

Graham R Foster (UK) and Ivan Gardini (Italy)

The COVID-19 pandemic: A unique opportunity to re-evaluate liver disease care

 

Marc Bourlière (France) and Ivan Gardini (Italy)

A new virus in the mix: learning from the pandemic to re-shape viral hepatitis care

 

Juan Turnes (Spain) and
Ivan Gardini (Italy)

Re-imagining viral hepatitis care:
keeping it simple

Best practices in liver disease care in the COVID-19 era

Please see the below infographics where you can explore how liver disease care has adapted in response to the COVID-19 pandemic and how these best practice examples could help to re-define the management of patients during COVID-19 and beyond.

The Hepatitis Intensive Test and Treat Initiative at HM Prison Bullingdon in
Bicester, UK

Emily Mongale, CARE UK and Elaine Lawson, Thames Valley HCP Op Network, UK

Co-screening for anti-SARS-CoV-2 and anti-HCV in Casola di Napoli, Italy

Ivan Gardini, EpaC Onlus, Monza, Italy

Uptake of telemedicine by a Hepatitis C treatment programme in Louisiana, USA

Tavell Kindall, St. Thomas Community Health Center, Louisiana, USA

Rapid implementation of telemedicine for HCV management in PWID during the COVID-19 pandemic

Anthony Martinez, 'La Bodega' Erie County Medical Centre (ECMC), Hepatology Clinic, New York, USA

Telepharmacy and home delivery of treatment implemented in 111 hospitals during the COVID-19 pandemic in Spain

Olga Delgado, Jordi Nicolás, José Antonio Marcos and Cecilia Martínez, Spanish Society of Hospital Pharmacy (SEFS), Spain

Telemedicine to treat patients with liver disease and after liver transplantation in outpatient clinics in
Sydney, Australia

Simone Strasser, Royal Prince Alfred Hospital, Sydney, Australia

Taking telemedicine further

Agenda

Presentation Faculty
Opening address: Creating possible Tram Tran (Gilead Sciences, US)
The COVID-19 pandemic: a unique opportunity to re-evaluate liver disease care

Chair: Graham Foster (UK)

Ivan Gardini (Italy)

A new virus in the mix: learning from the pandemic to re-shape viral hepatitis care 

Marc Bourlière (France)

Ivan Gardini (Italy)

Re-imagining viral hepatitis care: keeping it simple

Juan Turnes (Spain)

Ivan Gardini (Italy)

Close: Anticipating the ‘new normal’ in liver disease care

Graham Foster (UK)

Ivan Gardini (Italy)

Marc Bourlière (France)

Juan Turnes (Spain)

Chair: Graham Foster (UK)

Affiliation
Professor of Hepatology at Queen Mary University of London, and Consultant Hepatologist at Barts and The London NHS Trust, London, UK.

Biography
Graham R Foster is Professor of Hepatology at Queen Mary, University of London, and a Consultant Hepatologist at Barts and The London NHS Trust, both in London, UK. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992. Professor Foster has a long-standing interest in the management of chronic viral hepatitis and runs a clinical research programme studying the natural history of the disease, its impact upon patients and their communities, and novel therapies. He also supervises a laboratory research programme investigating novel replication systems for HCV. He is Editor of the Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is a past President of the British Association for the Study of the Liver and is an active participant in the English HCV Elimination programme.

Marc Bourlière (France)

Affiliation
Head of the Hepato-Gastroenterology Department at Saint Joseph Hospital in Marseille, France.

Biography
Marc Bourlière is Head of the Hepato-Gastroenterology Department at Saint Joseph Hospital in Marseille, France. He is also an Associate Professor at Paris Hospital Medical College. Dr Bourlière’s research has focused on the development of new antiviral therapies for HBV and HCV and, more recently, on the treatment of HCV in people who use drugs and those on opioid substitution therapy. He also belongs to the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and heads the ANRS group that coordinates hepatitis clinical therapeutic trials.

Tram Tran (Gilead Sciences, US)

Affiliation
Vice President, Medical Affairs, Gilead Sciences.

Biography

Tram Tran is an internationally renowned liver specialist and Vice President, Medical Affairs at Gilead Sciences, focused on liver diseases, fibrosis, recently COVID-19. Prior to working at Gilead she was the Medical Director of Liver Transplantation at Cedars-Sinai Medical Center, Los Angeles, CA, USA and Professor of Medicine at the David Geffen School of Medicine at UCLA for over 16 years. Her career research interests have been in viral hepatitis, liver disease in women and pregnancy for which she authored the ACG practice guidelines. She has authored and co-authored numerous abstracts, papers and books on liver disease, published in journals such as Hepatology, the New England Journal of Medicine and Liver Transplantation, and has served on the editorial board for Hepatology, the American Journal of Gastroenterology and Gastroenterology along with her role as AASLD Chair of the Practice Guidelines Committee. She maintains clinical and teaching activities in Los Angeles.

Juan Turnes (Spain)

Affiliation
Head of Gastroenterology and Hepatology Department, Complejo Hospitalario Universitario de Pontevedra, Galicia Sur Health Research Institute (IISGS).

Biography

Juan Turnes currently works as head of the department of digestive diseases at the Complejo Hospitalario Universitario de Pontevedra in the Vido region of Spain. In 2010 he gained his PhD in Medicine and Surgery with highest honours and in 2012 he gained a Master’s Degree in Medical and Clinical Management.

Dr Turnes’ research interests include the management of hepatitis C and HCC and has been been prinicipal investigator on many clinical trials. He is widely published in the field of hepatology and is affiliated with several different organisations. For example, since February 2017, Dr Turnes has been the Vice-secretary of the Spanish Association for the Study of the Liver (AEEH), as well as a member of the publishing board for the medical journal Gastroenterologia y Hepatologia since 2011.

Ivan Gardini (Italy)

Affiliation
President of EpaC Onlus, Italy.

Biography

Ivan Gardini is President of EpaC Onlus – a not-for-profit organisation focusing on hepatitis C and liver disease in Italy – and a previous Vice President of the European Liver Patients’ Association (ELPA). Since 20 years Ivan is a passionate activist and has been interviewed by many Italian media representatives on hepatitis C treatments and advocacy. Together the related scientific societies, he is leading the integration of testing of COVID-19 and hepatitis B and C viruses in Italy, where there is a high prevalence of hepatitis C and where COVID-19 hit first and hardest. He has on-the-ground experience of what ‘good’ looks like and how to adapt and change to take advantage of the situation rather than just talk about the challenges.


 

IHQ-LVD-2020-07-0018 Date of preparation: September 2020